Glooko
Glooko Company Growth, Stability & Outlook
This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Glooko and has not been reviewed or approved by Glooko.
What's the stability & growth outlook for Glooko?
Strengths in capital support, clinical scale, and expansion across devices, EHRs, and care settings are accompanied by partner‑dependence and areas where competitors lead (notably inpatient dosing), plus indications of workforce tightening. Together, these dynamics suggest a company extending its market presence with solid financial backing while needing to solidify hospital traction and partnership stability to sustain resilient growth.
Key Insight for Candidates
Defining tradeoff: Glooko is in a scale-up-by-expansion phase (big funding + hospital-to-home acquisition), trading rapid scope growth for significant integration and go-to-market complexity. This means execution risk and shifting priorities as inpatient workflows, EHR channels, and partnerships mature. Candidates should expect ambiguity, cross-functional integration work, and pressure for tangible outcomes.Evidence in Action
- Series F Powered Scaling — Documented organizational pattern: the 2024 $100M Series F and CEO Mike Alvarez appointment codify a deliberate scale-up phase. Employees see accelerated resourcing, clearer expansion priorities, and faster decision cycles to grow products, geographies, and life‑sciences programs.
- Hospital to Home Integration — Documented organizational pattern: the 2025 acquisition of Monarch Medical Technologies (EndoTool) establishes a 'hospital‑to‑home' glycemic management path. Teams work cross‑functionally to integrate inpatient workflows with ambulatory tools, creating resilient go‑to‑market motions and new clinical competencies for employees.
Positive Themes About Glooko
-
Strong Market Position & Advantage: Public disclosures describe Glooko as a leader among device‑agnostic, clinic‑integrated diabetes data platforms, supported by scale of 4.4M+ users and 10,000+ clinical locations. Broad device coverage and Epic Showroom availability reinforce its role in standard clinic workflows.
-
Investor Backing & Capital Strength: Recent financings include a $100M Series F in October 2024 and an additional Series F‑II round in September 2025, signaling strong capital support. Leadership changes tied to the raise were positioned to fund product expansion and go‑to‑market scaling.
-
Market Expansion: The 2025 acquisition of Monarch Medical Technologies (EndoTool) extends the platform from outpatient monitoring into inpatient glycemic management, advancing a “hospital‑to‑home” strategy. Additional device integrations (e.g., Abbott FreeStyle Libre, Roche Accu‑Chek SmartGuide in EMEA) and Epic distribution point to continued geographic and settings expansion.
Considerations About Glooko
-
Workforce Instability: Third‑party trackers pointed to possible layoffs around December 2025 (unquantified and unconfirmed by the company), suggesting potential cost tightening during scale‑up. Such signals can reflect market pressure in digital health.
-
Deteriorating Partnerships: Reports in 2025 indicated Tandem emphasizing its own portal over Glooko for some users, underscoring partner‑dependent dynamics that can shift. OEM device portals remaining strong defaults in single‑brand settings heighten this risk.
-
Weak Market Position & Pricing Challenges: In inpatient insulin‑dosing software, Glytec is widely cited as the U.S. category leader, leaving Glooko’s EndoTool as a challenger rather than the incumbent. This contrasts with Glooko’s outpatient strength and highlights competitive headwinds in hospitals.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
Glooko Insights
Glooko FAQs
Is This Your Company?
Claim Profile
